Brain natriuretic peptide (1-32) (human)
Cat. No. 3522
Biological ActivityEndogenous peptide secreted from cardiac ventricles in response to volume increase and pressure overload that acts as an agonist at atrial natriuretic peptide (ANP) receptor A (NRP1). Decreases de novo collagen synthesis and increases MMP gene expression in vitro. Exhibits natriuretic, vasodilatory and lusitropic activity and inhibits the sympathetic and renin-angiotensin-aldosterone systems in vivo.
(Modifications: Disulfide bridge between 10 - 26)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Heublein et al (2007) Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various forms of human B-type natriuretic peptide. Hypertension 49 1114. PMID: 17372040.
Wellard et al (2006) Natriuretic peptides, but not nitric oxide donors, elevate levels of cytosolic guanosine 3',5'-cyclic monophosphate in ependymal cells ex vivo. Neurosci.Lett. 392 187. PMID: 16278044.
Tsuruda et al (2002) Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ.Res. 91 1127. PMID: 12480813.
If you know of a relevant reference for Brain natriuretic peptide (1-32) (human) please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Brain natriuretic peptide (1-32) (human) from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Brain natriuretic peptide (1-32) (human), supplier, Endogenous, peptide, agonists, ANP, receptor, A, NRP1, Receptors, Atrial, Natriuretic, Peptide, Tocris Bioscience, Natriuretic Peptide Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Toll-like receptor (TLR) 5/Flagellin complex antagonistBioymifi
DR5 (TRAIL receptor) agonist; induces apoptosisBOP
Dual α9β/1α4β1 integrin inhibitor; preferentially mobilizes HSCs
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.